| |
| |
|
| Insider
Information: |
Harsch Mutya |
| Relationship: |
|
| City: |
Rehovot |
| State: |
L3 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
149,274 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$33,363 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
149,274 |
|
|
| Total
Value |
$33,363 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Foamix Pharmaceuticals Ltd |
FOMX |
CLO and General Counsel |
2020-03-09 |
0 |
2019-01-01 |
0 |
Premium* |
|
|
VYNE Therapeutics Inc |
VYNE |
|
2024-04-01 |
149,274 |
2020-03-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
37 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,127 |
55,127 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2019-04-01 |
4 |
S |
$3.75 |
$9,446 |
D/D |
(2,519) |
52,608 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2019-07-01 |
4 |
S |
$2.35 |
$1,502 |
D/D |
(639) |
51,969 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2019-09-30 |
4 |
D |
$3.07 |
$1,421 |
D/D |
(463) |
51,506 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2019-11-29 |
4 |
A |
$2.16 |
$9,249 |
D/D |
4,284 |
55,790 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2019-12-31 |
4 |
D |
$3.28 |
$2,027 |
D/D |
(618) |
55,172 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2020-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
41,299 |
96,471 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2020-03-02 |
4 |
A |
$2.68 |
$4,715 |
D/D |
1,761 |
98,232 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
58,191 |
58,191 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
CLO and General Counsel |
• – – |
2020-03-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(98,232) |
0 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-03-31 |
4 |
D |
$2.68 |
$4,524 |
D/D |
(1,688) |
56,503 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
118,683 |
175,186 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-04-06 |
4 |
D |
$1.40 |
$6,264 |
D/D |
(4,474) |
170,712 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
320,712 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-06-30 |
4 |
D |
$1.73 |
$3,152 |
D/D |
(1,822) |
318,887 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-09-30 |
4 |
D |
$1.66 |
$3,025 |
D/D |
(1,822) |
317,065 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-11-30 |
4 |
A |
$1.45 |
$15,115 |
D/D |
10,460 |
327,525 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2020-12-31 |
4 |
D |
$1.58 |
$2,879 |
D/D |
(1,822) |
325,703 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
29,213 |
110,638 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2021-03-31 |
4 |
D |
$6.84 |
$12,073 |
D/D |
(1,765) |
108,873 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2021-06-30 |
4 |
D |
$3.51 |
$12,464 |
D/D |
(3,551) |
105,322 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2021-09-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,859 |
166,181 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2021-09-30 |
4 |
D |
$1.39 |
$2,063 |
D/D |
(1,484) |
164,697 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2021-12-31 |
4 |
D |
$1.02 |
$1,514 |
D/D |
(1,484) |
163,213 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Legal Officer and GC |
• – – |
2022-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
238,213 |
0 |
- |
|
37 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
